Active site-blocked activated factor VII as an effective antithrombotic agent: Mechanism of action

Blood Coagulation and Fibrinolysis

Volumn 11, Issue 4 SUPPL. 1, 2000, Pages

  Rao, L V M ^a   Ezban, M ^b  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Active site inactivated factor VIIa; Factor VIIa; FFR FVIIa; Thrombosis; Tissue factor

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 7A; CELL SURFACE PROTEIN; THROMBOPLASTIN;

BLOOD CLOTTING; BLOOD VESSEL INJURY; CONFERENCE PAPER; HEMOSTASIS; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOGENESIS; THROMBOSIS;

EID: 0034040810     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200004001-00026     Document Type: Conference Paper

References (55)

1. Semeraro N, Colucci M. Tissue factor in health and disease. Thromb Haemost 1997; 78: 759-764.
2. Osterud B. Tissue factor: a complex biological role. Thromb Haemost 1997; 78: 755-758.
3. Taubman MB, Fallon JT, Schecter AD, Giesen P, Mendlowitz M, Fyfe BS, et al. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost 1997; 78: 200-204.
4. Rapaport SI, Rao LV. The tissue factor pathway: how it has become a 'prima ballerina'. Thromb Haemost 1995; 74: 7-17.
5. McNamara CA, Sarenbock IJ, Gimple LW, Fenton JW II, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 1993; 91: 94-98.
6. Gasic GP, Arenas CP, Gasic TB, Gasic GJ. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci USA 1992; 89: 2317-2320.
7. Ruf W, Mueller BM. Tissue factor signalling. Thromb Haemost 1999; 82: 175-182.
8. Harker LA, Hanson SR, Kelly AB. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. Thromb Haemost 1997; 78: 736-741.
9. Warr TA, Rao LV, Rapaport SI. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990; 75: 1481-1489.
10. Taylor FB Jr, Chang A, Ruf W, Morrissey JH, Hinshaw LB, Catlett R, et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33: 127-134.
11. Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Buller HR, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-120.
12. Pawashe AB, Golino P, Ambrosio G, Migliaccio F, Ragni M, Pascucci I, et al. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res 1994; 74: 56-63.
13. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91: 2850-2856.
14. Lindahl AK, Sandset PM, Thune-Wiiger M, Nordfang O, Sakariassen KS. Tissue factor pathway inhibitor prevents thrombus formation on procoagulant subendothelial matrix. Blood Coagul Fibrinolysis 1994; 5: 755-760.
15. Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor: potential therapeutic applications. Thromb Haemost 1997; 78: 471-477.
16. Coggins JR, Kray W, Shaw E. Affinity labelling of proteinases with tryptic specificity by peptides with C-terminal lysine chloromethyl ketone. Biochem J 1974; 137: 579-585.
17. Kettner C, Shaw E. Inactivation of trypsin-like enzymes with peptide of arginine chloromethyl ketone. Methods Enzymol. 1981; 80(Pt C): 826-842.
18. Bach R, Gentry R, Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. Biochemistry 1986; 25: 4007-4020.
19. Higashi S, Matsumoto N, Iwanaga S. Molecular mechanism of tissue factor-mediated acceleration of factor VIIa activity. J Biol Chem 1996; 271: 26569-26574.
20. Dickinson CD, Ruf W. Active site modification of factor VIIa affects interactions of the protease domain with tissue factor. J Biol Chem 1997; 272: 19875-19879.
21. Sørensen BB, Rao LVM. Interaction of factor VIIa and active site-inhibited factor VIIa with tissue factor. Blood Coagul Fibrinolysis 1998; 9 (suppl 1): S67-S71.
22. Sørensen BB, Persson E, Freskgård PO, Kjalke M, Ezban M, Williams T, Rao LV. Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor. J Biol Chem 1997; 272: 11863-11868.
23. Kjalke M, Oliver JA, Monroe DM, Hoffman M, Ezban M, Hedner U, Roberts HR. The effects of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration. Thromb Haemost 1997; 78: 1202-1208.
24. Orvim U, Barstad RM, Orning L, Petersen LB, Ezban M, Hedner U, Sakariassen KS. Antithrombotic efficacy of inactivated active site recombinant factor VIIa is shear dependent in human blood. Arterioscler Thromb Vasc Biol 1997; 17: 3049-3056.
25. Kjalke M, Monroe DM, Hoffman M, Oliver JA, Ezban M, Roberts HR. Active site-inactivated factors VIIa, Xa, and IXa inhibit individual steps in a cell-based model of tissue factor-initiated coagulation. Thromb Haemost 1998; 80: 578-584.
26. Kirchhofer D, Tschopp TB, Baumgartner HR. Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model. Arterioscler Thromb Vasc Biol 1995; 15: 1098-1106.
27. Lindahl AK, Wildgoose P, Lumsden AB, Allen R, Kelly AB, Harker LA, Hanson LA. Active site-inhibited FVIIa blocks tissue factor activity and prevents arterial thrombus formation in baboons (abstract). Circulation 1993; 88 (suppl): I47.
28. Harker LA, Hanson SR, Kelly AB. Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists. Thromb Haemost 1995; 74: 464-472.
29. Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE, et al. Influence of blockade at specific-levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995; 92: 3041-3050.
30. Courtman DW, Schwartz SM, Hart CE. Sequential injury of the rabbit abdominal aorta induces intramural coagulation and luminal narrowing independent of intimal mass: extrinsic pathway inhibition eliminates luminal narrowing. Circ Res 1998; 82: 996-1006.
31. Golino P, Ragni M, Cirillo P, D'Andrea D, Scognamiglio A, Ravera A, et al. Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis. Circ Res 1998; 82: 39-46.
32. Golino P, Cirillo P, D'Andrea D, Ragni M, Calabr P, Ravera M, et al. Antithrombotic effects of human recombinant, active site-blocked factor VIIa in a chronic rabbit model of intravascular thrombosis (abstract). Circulation 1998; 98: I727.
33. Arnljots B, Ezban M, Hedner U: Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa. J Vasc Surg 1997; 25: 341-346.
34. Holst J, Kristensen AT, Kristensen HI, Ezban M, Hedner U. Local application of recombinant active site-inhibited human clotting factor VIIa reduces thrombus weight and improves patency in a rabbit venous thrombosis model. Eur J Vasc Endvasc Surg 1998; 15: 515-520.
35. Taylor FB Jr, Chang ACK, Peer G, Li A, Ezban M, Hedner U. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8 but not tumor necrosis factor responses of the baboon to LD 100 Escherichia coli. Blood 1998; 91: 1609-1615.
36. Taylor FB Jr, Chang AC, Peer GT, Mather T, Blick K, Catlett R, et al. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood 1991; 78: 364-368.
37. Erhardsten E, Thomsen MS, Johannesen M, Falch JF, Bech RM. Efficacy and safety of FFR-FVIIa in healthy volunteers [abstract]. Circulation 1998; 98: I564.
38. Ruf W, Mueller BM. Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hematol 1996; 3: 379-384.
39. + signals in J82 cells, transfected COS-1 cells, Madin-Darby canine kidney cells and in human endothelial cells induced to synthesize tissue factor. J Biol Chem 1995; 270: 4650-4660.
40. Poulsen LK, Jacobsen N, Sørensen BB, Bergenhem NC, Kelly JD, Foster DC, et al. Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor. J Biol Chem 1998; 273: 6228-6232.
41. Pendurthi UR, Alok D, Rao LV. Binding of factor VIIa to tissue factor induces alterations in gene expression in human fibroblast cells: up-regulation of poly(A) polymerase. Proc Natl Acad Sci USA 1997; 94: 12598-12603.
42. + oscillations in Madin-Darby canine kidney cells only when proteolytically active. J Biol Chem 1996; 271: 29034-29042.
43. Sato Y, Asada Y, Marutsuka K, Hatakeyama K, Kamikubo Y, Sumiyoshi A. Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/factor VIIa complex. Thromb Haemost 1997; 78: 1138-1141.
44. Taniguchi T, Kakkar AK, Tuddenham EG, Williamson RC, Lemoine NR. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer. Cancer Res 1998; 58: 4461-4467.
45. Mueller BM, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest 1998; 101: 1372-1378.
46. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-744.
47. Rao LV, Rapaport SI. Cells and the activation of factor VII. Haemostasis 1996; 26 (suppl 1): 1-5.
48. Okazaki H, Majesky MW, Harker LA, Schwartz SM. Regulation of platelet-derived growth factor ligand and receptor gene expression by alpha-thrombin in vascular smooth muscle cells. Circ Res 1992; 71: 1285-1293.
49. Berk BC, Taubman MB, Griendling KK, Cargoe EJ Jr, Fenton JW, Brock TA. Thrombin-stimulated events in cultured vascular smooth-muscle cells. Biochem J 1991; 274: 799-805.
50. Hoffman M, Church FC. Response of blood leukocytes to thrombin receptor peptides. J Leukoc Biol 1993; 54: 145-151.
51. Grand RJ, Turnell AS, Grabham PW. Cellular consequences of thrombin-receptor activation. Biochem J 1996; 313: 353-368.
52. Camerer E, Kolsto AB, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996; 81: 1-41.
53. Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V, Mendlowitz M, et al. Tissue factor is rapidly induced in arterial smooth muscle cell after balloon injury. J Clin Invest 1993; 91: 2253-2259.
54. Hamik K, Setiad H, Bu G, McEver RP, Morrissey JH. Down-regulation of monocyte tissue factor mediated by tissue factor pathway inhibitor and the low density lipoprotein receptor-related protein. J Biol Chem 1999; 274: 4962-4969.
55. Iakhiaev A, Pendurthi UR, Voigt J, Ezban M, Rao LVM. Catabolism of factor VIIa bound to tissue factor in fibroblasts in the presence and absence of tissue factor pathway inhibitor. J Biol Chem 1999; 274: 36995-37003.